Conjugated equine oestrogen versus placebo in the management of menopausal symptoms

One hundred women underwent a 10-week sequential double-blind/crossover to compare conjugated equine oestrogen (Premarin, 0.625 mg and 1.25 mg) with one and two placebo tablets in the management of menopausal symptoms. Sixty-one subjects completed each of in the four regimens. Thirty-one of these continued with their own choice of regimen for a further nine months. Premarin 1.25 mg proved to be significantly more effective (P less than 0.01) in ameliorating menopausal symptoms than Premarin 0.625 mg and both levels of placebo. Premarin 1.25 mg was also preferred as the treatment of choice by the 31 women (P less than 0.001).